Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study

Autor: Philip, Philip A ^*, Lacy, Jill, Portales, Fabienne, Sobrero, Alberto, Pazo-Cid, Roberto, Manzano Mozo, José L, Kim, Edward J, Dowden, Scot, Zakari, Ahmed, Borg, Christophe, Terrebonne, Eric, Rivera, Fernando, Sastre, Javier, Bathini, Venu, López-Trabada, Daniel, Asselah, Jamil, Saif, Muhammad Wasif, Shiansong Li, Jack, Ong, Teng Jin, Nydam, Thomas, Hammel, Pascal

Publikováno v: In The Lancet Gastroenterology & Hepatology March 2020 5(3):285-294

P-286 Metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel (nab-P), bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer (MPC): an open-label, multicenter, single-arm, phase 1/2 study

Autor: Ocean Allyson, Picozzi Vincent, Sahai Vaibhav, Philip A. Philip, Ondovik Michael, Rocha Lima Caio, Manax Victoria, Saif Wasif, Simeone Diane, Shiansong Li Jack, Kalyan Aparna

Publikováno v: Annals of Oncology. 27:ii83

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a40d565d6bc6adf0ebe4d36635c8767
https://doi.org/10.1093/annonc/mdw199.276

P-216 - Treatment patterns and clinical outcomes in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: Analysis of US electronic health records from the Flatiron Health Database

Autor: Flick Elizabeth, Dawn, Shiansong Li, Jack, Jirau-Lucca, Gilbert, Ondovik, Michael, Nifenecker, Melissa, Fish, Susan, Liu, Helen, Hua Huang, Jian, Swern, Arlene, Louis, Chrystal

Publikováno v: In Annals of Oncology June 2017 28 Supplement 3:iii77-iii78

p53 Mutant Independently Impacts Risk: Analysis of Deletion 5q, Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Lenalidomide (LEN) in the MDS-004 Study

Autor: Saft, Leonie ^*, Shiansong Li, Jack ^*, Greenberg, Peter L., Sekeres, Mikkael A., Sanz, Guillermo F., Dreyfus, François ^*, Fenaux, Pierre, Swern, Arlene S. ^*, Sugrue, Mary M. ^*, Hellstrom-Lindberg, Eva

Publikováno v: In Blood 6 December 2014 124(21):414-414

nab -Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial.

Autor: Tabernero J; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Kunzmann V; Medizinische Klinik und Poliklinik II, University of Würzburg, Würzburg, Germany., Scheithauer W; Medizinische Universität Wien, Wien, Austria., Reni M; San Raffaele Scientific Institute, Milan, Italy., Shiansong Li J; Celgene Corporation, Summit, NJ, USA., Ferrara S; Celgene Corporation, Boudry, Switzerland., Djazouli K; Celgene Corporation, Paris, France.

Publikováno v: OncoTargets and therapy [Onco Targets Ther] 2017 Feb 02; Vol. 10, pp. 591-596. Date of Electronic Publication: 2017 Feb 02 (Print Publication: 2017).